Emma Iserman

3.9k total citations · 1 hit paper
22 papers, 2.4k citations indexed

About

Emma Iserman is a scholar working on Hematology, Genetics and General Health Professions. According to data from OpenAlex, Emma Iserman has authored 22 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 3 papers in Genetics and 3 papers in General Health Professions. Recurrent topics in Emma Iserman's work include Hemophilia Treatment and Research (12 papers), Social and Intergroup Psychology (3 papers) and Gender Diversity and Inequality (2 papers). Emma Iserman is often cited by papers focused on Hemophilia Treatment and Research (12 papers), Social and Intergroup Psychology (3 papers) and Gender Diversity and Inequality (2 papers). Emma Iserman collaborates with scholars based in Canada, United States and Netherlands. Emma Iserman's co-authors include R. Brian Haynes, Rebecca Jeffery, Nancy L Wilczynski, Alfonso Iorio, Arun Keepanasseril, Thomas Agoritsas, Tamara Navarro, Bhairavi Sivaramalingam, Chris Cotoi and Nicholas Hobson and has published in prestigious journals such as Journal of Personality and Social Psychology, Blood and Cochrane Database of Systematic Reviews.

In The Last Decade

Emma Iserman

21 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interventions for enhancing medication adherence

2014 1.7k citations Nancy L Wilczynski, Tamara Navarro et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emma Iserman Canada	10	1.1k	450	407	348	320	22	2.4k
Joke Denekens Belgium	18	769 0.7×	287 0.6×	719 1.8×	308 0.9×	121 0.4×	42	2.6k
Lena Ring Sweden	26	255 0.2×	293 0.7×	739 1.8×	307 0.9×	159 0.5×	53	3.6k
Karin Kjellgren Sweden	28	339 0.3×	259 0.6×	1.4k 3.4×	262 0.8×	763 2.4×	89	3.1k
Debora A. Paterniti United States	35	430 0.4×	337 0.7×	1.8k 4.5×	490 1.4×	118 0.4×	80	4.0k
Elaine Lehane Ireland	17	402 0.4×	178 0.4×	556 1.4×	171 0.5×	145 0.5×	63	1.5k
Summer L. Williams United States	10	331 0.3×	143 0.3×	747 1.8×	233 0.7×	101 0.3×	17	1.7k
Delesha M. Carpenter United States	29	231 0.2×	215 0.5×	898 2.2×	152 0.4×	86 0.3×	175	2.8k
Lynne Emmerton Australia	26	242 0.2×	730 1.6×	1.1k 2.8×	92 0.3×	101 0.3×	145	2.8k
Kelly B. Haskard United States	9	316 0.3×	137 0.3×	504 1.2×	184 0.5×	94 0.3×	10	1.4k
Carissa Bonner Australia	30	148 0.1×	356 0.8×	1.1k 2.7×	115 0.3×	237 0.7×	131	2.8k

Countries citing papers authored by Emma Iserman

Since Specialization

Citations

This map shows the geographic impact of Emma Iserman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Iserman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Iserman more than expected).

Fields of papers citing papers by Emma Iserman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Iserman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Iserman. The network helps show where Emma Iserman may publish in the future.

Co-authorship network of co-authors of Emma Iserman

This figure shows the co-authorship network connecting the top 25 collaborators of Emma Iserman. A scholar is included among the top collaborators of Emma Iserman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Iserman. Emma Iserman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matino, Davide, Federico Germini, Anthony K.C. Chan, et al.. (2024). Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia. 30(2). 345–354. 5 indexed citations

Matino, Davide, Pierre Chelle, Shannon Jackson, et al.. (2023). OC 24.1 Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates. Research and Practice in Thrombosis and Haemostasis. 7. 100443–100443. 1 indexed citations

Iorio, Alfonso, P Christoffersen, Davide Matino, et al.. (2023). Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes. Research and Practice in Thrombosis and Haemostasis. 7(3). 100106–100106. 1 indexed citations

Matino, Davide, Alfonso Iorio, Arun Keepanasseril, et al.. (2022). Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study. Research and Practice in Thrombosis and Haemostasis. 6(3). e12661–e12661. 5 indexed citations

Iserman, Emma, Pierre Chelle, Federico Germini, et al.. (2022). Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere. 6(4). e694–e694. 1 indexed citations

Iorio, Alfonso, David L. Page, Arun Keepanasseril, et al.. (2022). Reflections on the Canadian Bleeding Disorders Registry: Lessons Learned and Future Perspectives. Canadian Journal of Health Technologies. 2(8). 4 indexed citations

Poon, Man‐Chiu, Federico Germini, Arun Keepanasseril, et al.. (2022). Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry. Blood. 140(Supplement 1). 8465–8467. 1 indexed citations

Iserman, Emma, Pierre Chelle, Federico Germini, et al.. (2021). Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis. 19(8). 1896–1906. 16 indexed citations

Iserman, Emma, et al.. (2020). Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database. Blood. 136(Supplement 1). 21–22. 1 indexed citations

10.

Iorio, Alfonso, Emma Iserman, Victor S. Blanchette, et al.. (2017). Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 23(3). e170–e179. 67 indexed citations

11.

Wright, David, Amanda Young, Emma Iserman, et al.. (2014). The clinical relevance and newsworthiness of NIHR HTA-funded research: a cohort study. BMJ Open. 4(5). e004556–e004556. 5 indexed citations

12.

Jeffery, Rebecca, Tamara Navarro, Nancy L Wilczynski, et al.. (2014). Adherence measurement and patient recruitment methods are poor in intervention trials to improve patient adherence. Journal of Clinical Epidemiology. 67(10). 1076–1082. 33 indexed citations

13.

Agoritsas, Thomas, Emma Iserman, Nicholas Hobson, et al.. (2014). Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials. Implementation Science. 9(1). 125–125. 11 indexed citations

14.

Giguère, Anik, et al.. (2013). Developing a Two-Sided Intervention To Facilitate Shared Decision Making In Haemophilia: Decision Boxes For Clinicians and Brief Patient Decision Aids For Patients. Blood. 122(21). 1748–1748. 1 indexed citations

15.

Prorok, Jeanette, Emma Iserman, Nancy L Wilczynski, & R. Brian Haynes. (2012). The quality, breadth, and timeliness of content updating vary substantially for 10 online medical texts: an analytic survey. Journal of Clinical Epidemiology. 65(12). 1289–1295. 32 indexed citations

16.

Jeffery, Rebecca, et al.. (2012). Can computerized clinical decision support systems improve diabetes management? A systematic review and meta‐analysis. Diabetic Medicine. 30(6). 739–745. 66 indexed citations

17.

Logel, Christine, Gregory M. Walton, Steven J. Spencer, et al.. (2009). Interacting with sexist men triggers social identity threat among female engineers.. Journal of Personality and Social Psychology. 96(6). 1089–1103. 208 indexed citations

18.

Logel, Christine, Gregory M. Walton, Steven J. Spencer, et al.. (2009). “Interacting with sexist men triggers social identity threat among female engineers”: Correction.. Journal of Personality and Social Psychology. 97(4). 578–578. 4 indexed citations

19.

Logel, Christine, Emma Iserman, Paul G. Davies, Diane M. Quinn, & Steven J. Spencer. (2008). The perils of double consciousness: The role of thought suppression in stereotype threat. Journal of Experimental Social Psychology. 45(2). 299–312. 59 indexed citations

20.

Bell, Amy, et al.. (2003). Stereotype Threat and Women's Performance in Engineering. Journal of Engineering Education. 92(4). 307–312. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact